β Proteomics analysis showed that rencofilstat improved aberrant protein profiles in IPF tissues β β Superior...
EDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...
- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome...
EDISON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...
EDISON, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...
- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF...
EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...
000158377112/312023Q1false0.500015837712023-01-012023-03-3100015837712023-05-10xbrli:shares00015837712023-03-31i...
EDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads